US 11,684,571 B2
Methods of treating eosinophilic esophagitis
Brian A. Meltzer, Wilton, CT (US); and Gail M. Comer, Phoenixville, PA (US)
Assigned to Ellodi Pharmaceuticals, L.P., Lawrenceville, NJ (US)
Filed by Ellodi Pharmaceuticals, L.P., Lawrenceville, NJ (US)
Filed on May 3, 2021, as Appl. No. 17/306,458.
Application 17/306,458 is a continuation of application No. 16/992,671, filed on Aug. 13, 2020.
Application 16/992,671 is a continuation of application No. 16/131,812, filed on Sep. 14, 2018, granted, now 11,026,887.
Application 16/131,812 is a continuation of application No. 15/680,301, filed on Aug. 18, 2017, granted, now 10,105,315, issued on Oct. 23, 2018.
Claims priority of provisional application 62/489,292, filed on Apr. 24, 2017.
Claims priority of provisional application 62/461,317, filed on Feb. 21, 2017.
Claims priority of provisional application 62/376,703, filed on Aug. 18, 2016.
Prior Publication US 2021/0275438 A1, Sep. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/56 (2006.01); A61K 31/565 (2006.01); A61K 9/00 (2006.01)
CPC A61K 9/006 (2013.01) [A61K 31/56 (2013.01); A61K 31/565 (2013.01)] 24 Claims
 
1. A method of topically treating an esophageal stricture in a patient in need thereof with an orally disintegrating tablet comprising about 0.5 mg to about 18 mg of fluticasone or a pharmaceutically acceptable ester thereof, comprising:
administering the orally disintegrating tablet while the patient is lying down or immediately prior to the patient lying down,
wherein a therapeutically effective amount of the fluticasone, or pharmaceutically acceptable ester thereof, contacts the esophageal stricture, thereby reducing the severity of the esophageal stricture.